ERBB2 and cancer: Corresponding cumulative incidence of BRM at the 3-year time point for patients with HR-positive/ERBB2-negative cancer was 8.2% (95% CI, 6.7%-9.9%), ERBB2-positive/HR-positive cancer was 17.7% (95% CI, 13.5%-22.4%), ERBB2-positive/HR-negative cancer was 25.3% (95% CI, 19.2%-31.8%), and triple-negative MBC was 21.4% (95% CI, 16.5%-26.8%) (Figure).